Catalytic transfer hydrogenation (CTH) has gained attention as a potentially more sustainable process than conventional hydrogenation with H 2 gas.In this process, hydrogen is supplied in situ from a donor molecule without the need for high-pressure H 2 .We developed a conceptual commercial process for the transfer hydrogenation of furfural into furfuryl alcohol and performed techno-economic and greenhouse gas analyses aiming to identify bottlenecks and guide future research in this field.Two hydrogen donor compounds were considered: isopropanol and ethanol.Total capital investment varies between US$24.8-33.3 million for these processes, and the minimum selling price (MSP) for furfuryl alcohol is below the market price of US$1.52/kgonly with ethanol as hydrogen donor.The main impact on the profitability is from selling the dehydrogenated hydrogen donor as a co-product.Thus, low-cost hydrogen donors that generate high-value dehydrogenation products are required for this process to be competitive with conventional hydrogenation.In addition, utilizing a hydrogen donor that comes free of embodied impact and/or that avoids a GHG release is required for CTH to have lower greenhouse gas emissions intensity than conventional hydrogenation.
No takes yet. Share an insight, caveat, or question.
Fraga et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: